Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-04-01
2010-06-22
Goddard, Laura B (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387700, C435S007100
Reexamination Certificate
active
07741445
ABSTRACT:
The Breast Cancer Resistance Protein is described, as well as the cDNA encoding said protein. This protein has been found to confer resistance to cancer chemotherapeutic drugs.
REFERENCES:
patent: 5585479 (1996-12-01), Hoke
patent: 6060248 (2000-05-01), Lane
patent: 7541437 (2009-06-01), Ross et al.
patent: 2003/0232362 (2003-12-01), Komatani et al.
patent: 2005/0272684 (2005-12-01), Ross et al.
patent: WO 94/10303 (1994-05-01), None
patent: WO 98/55614 (1998-12-01), None
patent: WO 99/58675 (1999-11-01), None
patent: WO 00/18912 (2000-04-01), None
patent: WO 00 36101 (2000-06-01), None
patent: WO 03/107249 (2003-12-01), None
Allikmets et al, Cancer Research, Dec. 1, 1998, 58:53337-53339, IDS.
Christiansen et al (Mol Cancer Ther, 2004, 3:1493-1501).
Topp et al (Journal of Controlled Release, 1998, 53:15-23).
White et al. (2001, Ann. Rev. Med., 2001, 52:125-145).
Johnstone and Thorpe (Immunochemistry in Practice, 2nd Ed., 1987, Blackwell Scientific Publications, Oxford, pp. 49-50).
GenBank Accession No. AAC97367 (GI:4038352), publicly available on NCBI Dec. 21, 1998, IDS.
“Sequence alignment of SEQ ID No. 1 and AAC97367” printed Dec. 11, 2007, pp. 1-2, IDS.
U.S. Appl. No. 60/073,763, filed Feb. 5, 1998, p. 3, p. 6; claims p. 1-2; Figure 2A one page; total pages =5.
NCBI Accession No. CQ757490 printout for database entry dated Mar. 1, 2004.
Gura, “Antisense has Growing Pains,” Science, vol. 270, Oct. 27, 1995, pp. 575-577.
Bowie et al., Science, vol. 247, Mar. 16, 1990, pp. 1300-1310.
Lazar et al., Molecular and Cellular Biology, vol. 8(3), Mar. 1988, pp. 1247-1252.
Burgess et al., The Journal of Cell Biology, vol. 111, Nov. 1990, pp. 2129-2138.
Hillier et al., (W84773), Genbank Sequence Database (Accession W84357), Ntl. Ctr. For Biotech Info., Natl. Lib. Medicine, Bethesda, MD, 1995.
Knutsen et al., Amplification of 4q21-q22 and the MXR Gene in Independently Derived Mitoxantrone-Resistant Cell lines,Genes, Chromosomes and Cancer, 27:110-116, 2000.
Ross et al., Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitaxantrone-Selected Cell Lines.JNCI, 91(5):1-11, 1999.
Allikmets et al., Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the Expressed Sequence Tags database,Human Molecular Genetics5(1):1649-1655, 1996.
Cole et al., Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line,Science258(5088):1650-4, 1992;ErratuminScience260(5110):879, 1993.
Nakagawa et al., Reduced Intracellular Drug Accumulation in the Absence of P-Glycoprotein (mdr1) Overexpression in Mitoxantrone-resistant Human MCF-7 Breast Cancer Cells,Cancer Research52:6175-6181, 1992.
Yang et al., Cross-Resistance to Camptothecin Analogues in a Mitoxantrone-resistance Human Breast Carcinoma Cell Line is Not Due to DNA Topoisomerase I Alterations,Cancer Research55:4004-4009, 1995.
Chen et al., Characterization of Adriamycin-resistant Human Breast Cancer Cell Which Display Overexpression of a Novel Resistance-related Membrane Protein,J. Biol. Chem. 265(17):10073-10080, 1999.
Dietel et al., Membrane Vesicle Formation due Acquired Mitoxantrone Resistance in Human Gastric Carcinoma Cell Line EPG85-257,Cancer Research50:6100-6106, 1990.
Taylor et al., Different Mechanisms of Decreased Drug Accumulation in Doxorubicin and mitoxantrone resistant variants of the MCF7 Human Breast Cancer Cell line,J. Cancer63:923-929, 1991.
Radindran et al., Fumitremorigin C Reverse Multidrug Resistance in Cells Transfected with the Breast Cancer Resistance Protein,Cancer Research60:47-50, 2000.
Futscher et al., Analysis of MRP mRNA in Mitoxantrone-Selected, Multidrug-Resistant Human Tumor Cells,Biochemical Pharmacology47(9):1601-1606 (1994).
Dalton et al., Cytogenetic and Phenotypic Analysis of a Human Colon Carcinoma Cell Line Resistant to Mitoxantrone,Cancer Research48:1882-1888, 1998.
Lee et al., Reduced Drug Accumulation and Multidrug Resistance in Human Breast Cancer Cells without Associated P-Glycoprotein or MPR Overexpression,J. Cell. Biochem. 65:513-526, 1997.
Kellner et al., Decreased Drug Accumulation in a Mitoxantrone-Resistant Gastric Carcinoma cell Line in the Absence of P-Glycoprotein,Int. J. Cancer71:817-824, 1997.
Ma et al., Reduced Cellular Accumulation of Topotecan: a novel Mechanism of Resistance in a Human Ovarian Cancer Cell Line,British Journal of Cancer77(10):1645-1652, 1998.
Rabindran et al., Reversal of a Novel Multidrug Resistance Mechanism in Human Colan Carcinoma Cells by Fumitremorgin C,Cancer Research58:5850-5858, 1998.
Maliepaards et al., Overexpression of the BCRP/MXR/ABCP Gene in a Toptecan-selected Ovarian Tumor Cell Line,Cancer Research59:4559-4563, 1999.
Lage et al., Expression of the Novel Mitoxantrone Resistance Associated with Gene MXR7 in Colorectal Malignancies,International Journal of Clinical Pharmacology and Therapeutics36(1):58-60, 1998.
Allen et al., The Mouse Bcrp1/Mxr/Abcp Gene: Amplification and Overexpression in Cell Lines Selected Resistance Toptecan, Mitoxantrone, or Doxorubicin,Cancer Research59(17):4237-4240, 1999.
Hazlehurst et al., Multiple Mechanisms Confer Drug Resistance to Mitoxantrone in the Human 8226 Myeloma Cell Line,Cancer Research59:1-8, 2000.
Schneider et al., Multidrug Resistance-assocatied Protein Gene Overexpression and Reduced Drug Sensitivity of Topoisomerase II in a Human Breast Carcinoma MCF7 Cell Line Selected for Etoposide Resistance,Cancer Research54:152-158, 1994.
Fairchild et al., Isolated of Amplified and Overexpressed DNA sequences from Adriamycin-resistant Human Breast Cancer Cells,Cancer Research47:5141-5148, 1987.
Holm et al., Reversion of Multidrug Resistance in the P-glycoprotein-positive Human Pancreatic Cell Line 1 (EPP85-181RDB) by Introduction of a Hammerhead Ribzyme,Br. J. Cancer70(2):239-243, 1994.
Ross, D., Novel Mechanisms of Drug Resistance in Leukemia,Leukemia14(3):467-473, 2000.
Bingham et al., Cloning of DNA Sequences from the White Locus ofD. melanogasterby a Novel and General Method,Cell25:693-704, 1981.
Pugh et al., Studies on the Mechanism of Fatty Acid Synthesis,J. Biol. Chem. 240(12):4727-4733, 1965.
O'Hare et al., DNA Sequence of the White Locus ofDrosophila melanogaster, J. Mol. Biol. 180:437-455, 1984.
Brangi et al., Camptothecin Resistance: Role of the ATP-binding Cassette (ABC), Mitoxantrone-resistance Half Transporter (MXR), and Potential for Glucuronidation in MXR-expressing Cells,Cancer Research59:5938-5946, 1999.
Biedler et al., Cellular Resistance to Actinomycin D in Chinese Hamster Cells in Vitro: Cross Resistance, Radioautographic and Cytogenetic Studies,Cancer Research30:1174-1184, 1970.
Harker et al., Multidrug Resistance in Mitoxantrone-selected HL-60 Leukemia Cells in the Absence of P-Glycoprotein Overexpression,Cancer Research49:4542-4549, 1989.
Skehan et al., New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening,J. Natl. Cancer Inst. 82(13):1107-1112, 1990.
Kohler et al., Derivation of Specific Antibody-Producing Tissue Culture and Tumor Lines by Cell Fusion,Eur. J. Immunol. 6:511-519, 1976.
Liang et al., Differential Display and Cloning of Messenger RNAs from Human Breast Cancer versus Mammary Epithelial Cells,Cancer Research52:6966-6968, 1992.
Ling et al., Reduced Permeability in CHO Cells as a Mechanism of Resistance to Colchicine,J. Cell Physiol. 83:106-116, 1974.
Kohler et al., Fusion between Immunoglobuline-secreting and Nonsecreting Myeloma Cell Lines,Eur. J. Immunol. 6:292-295, 1976.
Liang et al., Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction,Science257:967-971, 1992.
Sequence of a cDNA from theDrosophila melanogasterWhite Gene,Nucleic Acids Research18(6):1633, 1990.
Kohler et al., Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,Nature256(5517):495-497, 1975.
Kawaharata et al., Decreased Sensitivity of Carcinoembryonic Antigen cDNA-Transfected Cells to Adriamycin,Int. J. Cancer72:377-382, 1997.
Yu et al., Two COOH-Terminal Truncated Cytoplasimc Forms of Topoisomerase II in a VP-16-S
Abruzzo Lynne V.
Doyle L. Austin
Ross Douglas D
Goddard Laura B
Roylance Abrams Berdo & Goodman LLP
University of Maryland Baltimore
LandOfFree
Breast cancer resistance protein (BCRP) antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Breast cancer resistance protein (BCRP) antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Breast cancer resistance protein (BCRP) antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4152122